drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous genetically modified T cells engineered ex vivo to express a chimeric antigen receptor targeting a myeloma-associated surface antigen; administered as a CAR T cell infusion to drive antigen-dependent T-cell activation, proliferation, cytokine release, and cytotoxic killing of malignant plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered ex vivo to express a chimeric antigen receptor recognizing a myeloma-associated surface antigen. Upon antigen binding, CAR signaling (CD3ΞΆ with costimulation) drives antigen-dependent activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of malignant plasma cells in an MHC-independent manner, with in vivo expansion and persistence enabling sustained antitumor activity.
drug_name
CT071 (autologous CAR T cells)
nct_id_drug_ref
NCT06407947